RxDoctor Payments Data

Karen Lindower, DO

Family Medicine · Hillsdale, MINPI 1033117627

Payments from drug & device makers

$11,271in general payments, 2019–2025

Across 674 payments — averaging $16.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Pfizer$942
  • AstraZeneca$919
  • Novo Nordisk$888
  • Lilly USA, LLC$838
  • GSK$594
  • plus $6K from 38 others

What the payments were for

  • Food & beverage$11,10799%
  • Education$1641%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,271 in reported general payments places this provider in the 95th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$44,472
Medicare patients
130
Services billed
744

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin101$119,100
MounjaroTirzepatide108$115,686
FarxigaDapagliflozin Propanediol109$102,366
OzempicSemaglutide93$101,282
TrulicityDulaglutide77$89,196
Trelegy ElliptaFluticasone/Umeclidin/Vilanter108$77,469
EliquisApixaban64$56,037
XareltoRivaroxaban54$43,889
Nurtec OdtRimegepant Sulfate12$23,589
JanuviaSitagliptin Phosphate20$20,031
LinzessLinaclotide23$15,731
MyrbetriqMirabegron11$10,513
Fluticasone Propionate HfaFluticasone Propionate12$4,700
Levothyroxine Sodium363$4,430
Atorvastatin Calcium288$4,406

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$838$204,882185 claims
Boehringer IngelheimJardiance$226$119,100101 claims
AstraZenecaFarxiga$919$102,366109 claims
Novo NordiskOzempic$888$101,28293 claims
PfizerEliquis, Nurtec Odt$942$79,62676 claims
GSKTrelegy Ellipta$594$77,469108 claims
Johnson & JohnsonXarelto$501$43,88954 claims
MerckJanuvia$152$20,03120 claims
AbbVieLinzess, Synthroid$1,553$17,19147 claims
Astellas Pharma US IncMyrbetriq$221$10,51311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Hillsdale

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →